- Home
- PCQ vs BSX Comparison
PCQ vs BSX Comparison
Compare PCQ & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- BSX
- Stock Information
- Founded
- PCQ 2001
- BSX 1979
- Country
- PCQ United States
- BSX United States
- Employees
- PCQ N/A
- BSX N/A
- Industry
- PCQ Investment Managers
- BSX Medical/Dental Instruments
- Sector
- PCQ Finance
- BSX Health Care
- Exchange
- PCQ Nasdaq
- BSX Nasdaq
- Market Cap
- PCQ N/A
- BSX 138.4B
- IPO Year
- PCQ N/A
- BSX 1992
- Fundamental
- Price
- PCQ $8.66
- BSX $102.73
- Analyst Decision
- PCQ
- BSX Strong Buy
- Analyst Count
- PCQ 0
- BSX 23
- Target Price
- PCQ N/A
- BSX $110.57
- AVG Volume (30 Days)
- PCQ 69.6K
- BSX 10.3M
- Earning Date
- PCQ 01-01-0001
- BSX 04-23-2025
- Dividend Yield
- PCQ 4.63%
- BSX N/A
- EPS Growth
- PCQ N/A
- BSX 15.23
- EPS
- PCQ N/A
- BSX 1.37
- Revenue
- PCQ N/A
- BSX $17,554,000,000.00
- Revenue This Year
- PCQ N/A
- BSX $15.77
- Revenue Next Year
- PCQ N/A
- BSX $10.33
- P/E Ratio
- PCQ N/A
- BSX $75.05
- Revenue Growth
- PCQ N/A
- BSX 19.36
- 52 Week Low
- PCQ $8.19
- BSX $70.97
- 52 Week High
- PCQ $10.50
- BSX $107.17
- Technical
- Relative Strength Index (RSI)
- PCQ 54.28
- BSX 61.22
- Support Level
- PCQ $8.13
- BSX $92.70
- Resistance Level
- PCQ $8.58
- BSX $102.37
- Average True Range (ATR)
- PCQ 0.14
- BSX 2.95
- MACD
- PCQ 0.05
- BSX 1.17
- Stochastic Oscillator
- PCQ 96.36
- BSX 97.14
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.